First description of an uterine perforation potentially imputable to treatment with bevacizumab

Author： Uguen Thomas   Leconte Bérengère   Desgrippes Romain   Tchoundeu Belinda   Bretagne Jean François   Manfredi Sylvain  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.51, Iss.8, 2012-11, pp. : 1102-1104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nasal septum perforation and bevacizumab

By Power Derek  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 89-93

Humana Press, Inc

Access to resources Recommend Favorite

Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer

By Saif Muhammad   Elfiky Aymen   Salem Ronald  

Annals of Surgical Oncology, Vol. 14, Iss. 6, 2007-06 ,pp. : 1860-1869

Springer Publishing Company

Access to resources Recommend Favorite

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study

By Rosati Gerardo   Avallone Antonio   Aprile Giuseppe   Butera Alfredo   Reggiardo Giorgio   Bilancia Domenico  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 257-264

Springer Publishing Company

Access to resources Recommend Favorite

Uterine perforation at the time of brachytherapy for carcinoma of the cervix

By Irvin W.   Rice L.   Taylor P.   Andersen W.   Schneider B.  

Gynecologic Oncology, Vol. 90, Iss. 1, 2003-07 ,pp. : 113-122

Elsevier

Access to resources Recommend Favorite

Bevacizumab: In the Treatment of Colorectal Cancer

By Croom Katherine F.   Foster Rachel H.  

American Journal of Cancer, Vol. 3, Iss. 3, 2004-01 ,pp. : 187-194

Adis International

Access to resources Recommend Favorite